Porphyrias: A 2015 update.

The hereditary porphyrias comprise a group of eight metabolic disorders of the heme biosynthesis pathway. Each porphyria is caused by abnormal function at a separate enzymatic step resulting in a specific accumulation of heme precursors. Porphyrias are classified as hepatic or erythropoietic, based on the organ system in which heme precursors (δ-aminolevulinic acid [ALA], porphobilinogen and porphyrins) are overproduced. Clinically, porphyrias are characterized by acute neurovisceral symptoms, skin lesions or both. However, most if not all the porphyrias impair hepatic or gastrointestinal function. Acute hepatic porphyrias present with severe abdominal pain, nausea, constipation, confusion and seizure, which may be life threatening, and patients are at risk of hepatocellular carcinoma without cirrhosis. Porphyria Cutanea presents with skin fragility and blisters, and patients are at risk of hepatocellular carcinoma with liver iron overload. Erythropoietic protoporphyria and X-linked protoporphyria present with acute painful photosensitivity, and patients are at risk of acute liver failure. Altogether, porphyrias are still underdiagnosed, but once they are suspected, early diagnosis based on measurement of biochemical metabolites that accumulate in the blood, urine, or feces is essential so specific treatment can be started as soon as possible and long-term liver complications are prevented. Screening families to identify presymptomatic carriers is also crucial to prevent overt disease and chronic hepatic complications.

[1]  M. Laguno,et al.  Treatment of chronic hepatitis with boceprevir leads to remission of porphyria cutanea tarda , 2014, The British journal of dermatology.

[2]  T. Lefèbvre,et al.  Comprehensive cytochrome P450 CYP1A2 gene analysis in French caucasian patients with familial and sporadic porphyria cutanea tarda , 2012, The British journal of dermatology.

[3]  E. Marchesini,et al.  Long‐term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria , 2015, The British journal of dermatology.

[4]  J. Phillips,et al.  A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda , 2007, Proceedings of the National Academy of Sciences.

[5]  P. Harper,et al.  High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria , 2013, Journal of Inherited Metabolic Disease.

[6]  S. Sandberg,et al.  European specialist porphyria laboratories: diagnostic strategies, analytical quality, clinical interpretation, and reporting as assessed by an external quality assurance program. , 2011, Clinical chemistry.

[7]  P. Bauer,et al.  Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias. , 2015, Journal of hepatology.

[8]  S. Ducamp,et al.  Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP). , 2013, Human molecular genetics.

[9]  M. Badminton,et al.  Liver transplantation as a cure for acute intermittent porphyria , 2004, The Lancet.

[10]  D. Bissell,et al.  Role of delta-aminolevulinic acid in the symptoms of acute porphyria. , 2015, The American journal of medicine.

[11]  S. Sandberg,et al.  The incidence of inherited porphyrias in Europe , 2013, Journal of Inherited Metabolic Disease.

[12]  P. Beaune,et al.  Urinary metabolic fingerprint of acute intermittent porphyria analyzed by (1)H NMR spectroscopy. , 2014, Analytical chemistry.

[13]  Ó. Pozo,et al.  Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study , 2014, Orphanet Journal of Rare Diseases.

[14]  J. Deybach,et al.  High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. , 2015, Kidney international.

[15]  P. Reynier,et al.  Pro-oxidant effect of ALA is implicated in mitochondrial dysfunction of HepG2 cells. , 2014, Biochimie.

[16]  J. Deybach,et al.  La protoporphyrie érythropoïétique : une maladie, deux gènes et trois mécanismes moléculaires , 2010 .

[17]  S. Kersten,et al.  Peroxisome proliferator-activated receptor alpha controls hepatic heme biosynthesis through ALAS1. , 2009, Journal of molecular biology.

[18]  H. Puy,et al.  Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model. , 2006, Physiological research.

[19]  A. Singal,et al.  Liver transplantation in the management of porphyria , 2014, Hepatology.

[20]  G. Elder.  88 – Porphyria Cutanea Tarda and Related Disorders , 2003 .

[21]  H. Bonkovsky,et al.  Loss-of-Function Ferrochelatase and Gain-of-Function Erythroid-Specific 5-Aminolevulinate Synthase Mutations Causing Erythropoietic Protoporphyria and X-Linked Protoporphyria in North American Patients Reveal Novel Mutations and a High Prevalence of X-Linked Protoporphyria , 2013, Molecular Medicine.

[22]  P. Ponka.  Cell biology of heme. , 1999, The American journal of the medical sciences.

[23]  C. Beaumont,et al.  ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. , 2011, Blood.

[24]  M. Badminton,et al.  The cutaneous porphyrias. , 2014, Dermatologic clinics.

[25]  A. Finlay,et al.  A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases , 2012, The British journal of dermatology.

[26]  J. Alpert,et al.  A bridge too far: a critique of the new ACGME duty hour requirements. , 2012, The American journal of medicine.

[27]  M. Worwood,et al.  Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. , 2007, Blood.

[28]  C. Beaumont,et al.  Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model. , 2011, Gastroenterology.

[29]  H. Bonkovsky,et al.  Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. , 2014, The American journal of medicine.

[30]  C. Beaumont,et al.  Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. , 2007, Blood.

[31]  M. Katze,et al.  Down-regulation of hepcidin in porphyria cutanea tarda. , 2008, Blood.

[32]  P. Harper,et al.  Combined liver and kidney transplantation in acute intermittent porphyria , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[33]  S. Kersten,et al.  ' s personal copy Peroxisome Proliferator-Activated Receptor α Controls Hepatic Heme Biosynthesis Through ALAS 1 , 2009 .

[34]  Joanne,et al.  C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. , 2008, American journal of human genetics.

[35]  J. Deybach,et al.  Erythropoietic protoporphyria , 2009, Orphanet journal of rare diseases.

[36]  S. Ducamp,et al.  Late-onset X-linked dominant protoporphyria: an etiology of photosensitivity in the elderly. , 2013, The Journal of investigative dermatology.

[37]  V. Desquiret-Dumas,et al.  Acute intermittent porphyria causes hepatic mitochondrial energetic failure in a mouse model. , 2014, The international journal of biochemistry & cell biology.

[38]  P. Harper,et al.  Hepatocyte Transplantation Ameliorates the Metabolic Abnormality in a Mouse Model of Acute Intermittent Porphyria , 2014, Cell transplantation.

[39]  C. Lim,et al.  Porphomethene inhibitor of uroporphyrinogen decarboxylase: analysis by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. , 2007, Biomedical chromatography : BMC.

[40]  Dieter Jahn,et al.  Structure and function of enzymes in heme biosynthesis , 2010, Protein science : a publication of the Protein Society.

[41]  R. Deulofeu,et al.  Increased serum hepcidin levels in patients with porphyria cutanea tarda , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[42]  M. Lalanne,et al.  Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria , 2013, Proceedings of the National Academy of Sciences.

[43]  X. Schneider-Yin,et al.  Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria , 2015, Expert review of clinical pharmacology.

[44]  P. Harper,et al.  Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias. , 2000, Scandinavian journal of clinical and laboratory investigation.

[45]  H. Heimpel,et al.  Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations , 2011, Human mutation.

[46]  G. Murphy.  Diagnosis and management of the erythropoietic porphyrias , 2003, Dermatologic therapy.

[47]  D. Richardson,et al.  Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol , 2010, Proceedings of the National Academy of Sciences.

[48]  H. Bonkovsky,et al.  Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrias , 2014, Metabolites.

[49]  C. Ged,et al.  87 – Congenital Erythropoietic Porphyria , 2003 .

[50]  C. Beaumont,et al.  Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. , 2006, American journal of human genetics.

[51]  P. Ponka,et al.  Iron overload in human disease. , 2012, The New England journal of medicine.

[52]  E. Innala,et al.  Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15‐year follow‐up in northern Sweden , 2011, Journal of internal medicine.

[53]  H. Puy,et al.  Role of two nutritional hepatic markers (insulin‐like growth factor 1 and transthyretin) in the clinical assessment and follow‐up of acute intermittent porphyria patients , 2009, Journal of internal medicine.

[54]  R. Desnick,et al.  RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice , 2014, Proceedings of the National Academy of Sciences.

[55]  G. Song,et al.  Liver transplantation for acute-on-chronic liver failure from erythropoietic protoporphyria , 2012, Clinical and Molecular Hepatology.

[56]  R. Desnick,et al.  Molecular Expression and Characterization of Erythroid-Specific 5-Aminolevulinate Synthase Gain-of-Function Mutations Causing X-Linked Protoporphyria , 2013, Molecular Medicine.

[57]  J. Deybach,et al.  Hepatocellular carcinoma without cirrhosis: think acute hepatic porphyrias and vice versa , 2011, Journal of internal medicine.

[58]  M. F. Stewart,et al.  Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. , 2009, The Journal of investigative dermatology.

[59]  S. Thunell.  Porphyrins, porphyrin metabolism and porphyrias. I. Update , 2000, Scandinavian journal of clinical and laboratory investigation.

[60]  H. Bonkovsky,et al.  Hepatitis C, porphyria cutanea tarda and liver iron: an update , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[61]  D. Freeman,et al.  Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[62]  Jiandie D. Lin,et al.  Nutritional Regulation of Hepatic Heme Biosynthesis and Porphyria through PGC-1α , 2005, Cell.

[63]  C. Handschin,et al.  Identification of the xenosensors regulating human 5-aminolevulinate synthase , 2004, Proceedings of the National Academy of Sciences of the United States of America.